Dr. Dahiyat has been Xencor’s president and chief executive officer since the Company’s incorporation in August 1997, and is the co-founder of Xencor, and co-inventor of Xencor’s breakthrough XmAb® technology. He has led the Company in raising over $460 million in public and private financing, creating a diverse portfolio of monoclonal antibody clinical programs for the treatment of life-threatening and debilitating diseases, and establishing alliances with leading biopharmaceutical companies that generated over $200 million in upfront payments.

Dr. Dahiyat holds a Ph.D. in Chemistry from Caltech and B.S. and M.S.E. degrees in Biomedical Engineering from the Johns Hopkins University. He has co-authored numerous scientific papers in the fields of protein design and drug delivery, is an inventor of 33 US and numerous foreign patents, and has received scientific awards from the American Chemical Society, the Controlled Release Society, the Protein Society and Caltech.

Dr. Baracchini joined Xencor as chief business officer in January 2010. He has more than 15 years of experience in structuring and negotiating research and development partnerships, mergers and acquisitions, and in-licensing agreements. To date, Dr. Baracchini has negotiated more than 60 business transactions with multinational and Asian pharmaceutical firms, biotechnology companies and leading universities.

Most recently, he served as senior vice president of business development at Metabasis Therapeutics until its merger with Ligand Pharmaceuticals in 2009. Prior to joining Metabasis, Dr. Baracchini was vice president of business development at Elitra Pharmaceuticals, and the director of business development at Agouron Pharmaceuticals until its acquisition by Warner-Lambert in 1999. Prior to that, he was assistant director of business development at Isis Pharmaceuticals.

Dr. Baracchini holds a Ph.D. in molecular and cell biology from the University of Texas at Dallas and conducted his postdoctoral research at UCSD and The Scripps Research Institute. He also earned an M.B.A. from the University of California, Irvine, and a B.S. in microbiology from the University of Notre Dame.

Dr. Desjarlais oversees all aspects of discovery and research at the company including technology development, protein and antibody engineering and generation of drug candidates. Prior to joining Xencor, Dr. Desjarlais was an Assistant Professor of Chemistry at Penn State University, where he developed protein engineering methods similar to Xencor’s PDA® technology platform. Dr. Desjarlais received a B.S. in Physics from the University of Massachusetts and a Ph.D. in Biophysics from Johns Hopkins University. He then conducted postdoctoral research at the University of California, Berkeley. Dr. Desjarlais has driven the company’s technology development and engineering efforts for over 5 years and participated in the business development and intellectual property strategies.

Paul A. Foster, M.D. joined us as Chief Medical Officer in January 2010. Dr. Foster has 27 years of experience in a career spanning academic basic research, academic medical practice, research & development, product development, clinical development, drug safety, medical affairs, regulatory affairs, and product commercialization. From June 2008 through May 2009 he served as Chief Medical Officer for Cardium Therapeutics and prior to joining Xencor provided Medical/Clinical consulting services as SVP Development and Chief Medical Officer of Development and Strategic Consulting Associates, LLC. He has held senior leadership positions in both large and small biopharmaceutical companies including Biogen Idec, IDEC Pharmaceuticals, Abbott Laboratories, Alpha Therapeutics, Reata Pharmaceuticals, Cardium Therapeutics and Dade Behring. He has experience with the development of biologics, small molecules, and in-vitro diagnostics in therapeutic areas including oncology, hematology, inflammation and autoimmune diseases. Dr. Foster received his M.D. from Duke University School of Medicine and trained in Internal Medicine and Hematology/Oncology, and received a Bachelor of Science in Chemistry degree from the University of Michigan.

Mr. Kuch has primary responsibility for financial reporting, budgeting, cash-flow management, investments, and facility issues for the company. He has extensive experience working with emerging companies through the IPO process. Previously he worked over 15 years in public accounting most recently as a Director at Price Waterhouse. Mr. Kuch is a C.P.A. and received his B.S. and M.S. in Accounting from the University of Illinois.

Lloyd Rowland joined Xencor as Acting General Counsel in April 2014, and was appointed Senior Vice President, General Counsel, Secretary and Chief Compliance Officer, in August 2014. Mr. Rowland has more than 25 years of experience in corporate, securities and pharmaceutical/biotechnology law and has served as general counsel to three public life science companies.

Prior to his employment at Xencor, Mr. Rowland held several positions at Amylin Pharmaceuticals, Inc., including Vice President and Chief Compliance Officer from June 2010 to January 2013; Vice President, Governance and Compliance, Secretary, and Chief Compliance Officer from February 2007 to June 2010; and Vice President, Legal, Secretary, and General Counsel from September 2001 to February 2007. Prior to that, Mr. Rowland served as Vice President, General Counsel, and Secretary of Alliance Pharmaceutical Corp. Earlier, Mr. Rowland served as Vice President and Senior Counsel, Finance and Securities, at Imperial Savings Association and was engaged in the private practice of corporate law with the San Diego, California, law firm of Gray, Cary, Ames & Fry, and the Houston, Texas, law firm of Bracewell & Patterson.

Mr. Rowland received a B.S from Southern Methodist University and a J.D. from Emory University.

Xencor © Copyright 2018